Table 1 Clinical characteristics, laboratory measurements, complications during hospitalization and treatment before discharge of recovered COVID-19 patients
From: Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance
Characteristic | Total COVID-19 patients (n = 44) | LGE (N = 13) | Non-LGE (N = 31) | P-value |
|---|---|---|---|---|
Age (years) | 47.6 ± 13.3 | 53.2 ± 14.5 | 45.2 ± 12.43 | 0.07 |
Gender | 19 (43.2%) | 4 (30.8%) | 15 (48.4%) | 0.34 |
BSA (kg/m2) | 1.76 ± 0.19 | 1.73 ± 0.17 | 1.77 ± 0.2 | 0.63 |
Heart rate (bpm) | 66.2 ± 11.7 | 64.1 ± 6.8 | 67.0 ± 13.2 | 0.32 |
Time between hospital discharge and CMR (days) | 102.5 ± 20.6 | 100.8 ± 20.3 | 103.3 ± 21.0 | 0.72 |
Regular exercise | 10 (22.7%) | 3 (23.1%) | 7 (22.6%) | 1.0 |
Smoke | 1 (2.3%) | 0 | 1 (3.2%) | NA |
Alcohol | 3 (6.8%) | 1 (7.7%) | 2 (6.5%) | 1.0 |
NYHA I/II/III/IV | 21/13/8/2 | 4/5/3/1 | 17/8/5/1 | 0.52 |
Clinical COVID-19 pneumonia types, moderate/severe/critical | 32/11/1 | 7/5/1 | 25/6/0 | 0.10 |
Comorbidities | ||||
Hypertension | 11 (25.0%) | 5 (38.5%) | 6 (19.4%) | 0.18 |
Diabetes mellites | 8 (18.2%) | 2 (15.4%) | 6 (19.4%) | 1.0 |
Hyperlipidemia | 16 (36.4%) | 3 (23.1%) | 13 (41.9%) | 0.31 |
Chronic obstructive pulmonary disease | 0 | 0 | 0 | NA |
Cerebrovascular disease | 0 | 0 | 0 | NA |
Chronic renal diseases | 0 | 0 | 0 | NA |
Hepatitis B | 2 (4.6%) | 1 (7.7%) | 1(3.2%) | 0.51 |
Laboratory findings | ||||
CPK (u/l)* | 69 (14–141) | 57 (45–167) | 76 (45–142) | 0.85 |
CKMB (ng/ml)* | 0.33 (0.18–0.64) | 0.32 (0.11–0.73) | 0.33 (0.19–0.64) | 0.86 |
MYO (ng/ml) | 56.8 ± 42.7 | 66.9 ± 59.7 | 52.6 ± 33.6 | 0.31 |
TnI (ng/ml)* | 0.02 (0.01–0.02) | 0.02 (0.01–0.04) | 0.01 (0.01–0.02) | 0.04 |
CRP (mg/l) | 43 ± 43 | 55 ± 54 | 38 ± 37 | 0.24 |
Potassium (mmol/l) | 3.8 ± 0.3 | 3.7 ± 0.3 | 3.8 ± 0.3 | 0.24 |
Calcium (mmol/l) | 1.3 ± 0.2 | 1.3 ± 0.3 | 1.3 ± 0.2 | 0.33 |
Other complications during hospitalization | ||||
cardiac arrythmia | 0 | 0 | 0 | NA |
Renal injury | 4 (9.1%) | 1 (7.7%) | 3 (9.7%) | 1.0 |
Liver injury | 19 (43.2%) | 5 (38.5%) | 14 (45.2%) | 0.68 |
Treatment before discharge | Â | Â | Â | Â |
Antiviral therapy | 24 (54.5%) | 9 (69.2%) | 15 (48.4%) | 0.21 |
Antibiotic therapy | 12 (27.3%) | 5 (38.5%) | 7 (22.6%) | 0.28 |
Corticosteroids | 13 (29.6%) | 6 (46.2%%) | 7 (22.6%) | 0.12 |
Non-invasive ventilation of high-flow nasal cannula oxygen | 10 (22.7%) | 5 (38.5%) | 5 (16.1%) | 0.11 |
Intravenous immunoglobulin | 2 (4.6%) | 1 (7.7%) | 1 (3.2%) | 0.51 |
ACEI/ARB | 2 (4.6%) | 1 (7.7%) | 1 (3.2%) | 0.51 |